Aouizerat B, Garcia J, Domingues C, Xu K, Quach B, Page G
J Acquir Immune Defic Syndr. 2024; 97(2):156-164.
PMID: 39250649
PMC: 11752676.
DOI: 10.1097/QAI.0000000000003472.
Shin S, Mudvari P, Thaploo S, Wheeler M, Douek D, Quintana F
Nat Protoc. 2024; 19(11):3191-3218.
PMID: 39039320
PMC: 11537836.
DOI: 10.1038/s41596-024-01021-y.
Solis-Leal A, Boby N, Mallick S, Cheng Y, Wu F, De La Torre G
Sci Transl Med. 2023; 15(726):eadi9867.
PMID: 38091409
PMC: 11244655.
DOI: 10.1126/scitranslmed.adi9867.
Zhang C, Zaman L, Poluektova L, Gorantla S, Gendelman H, Dash P
Pathogens. 2023; 12(7).
PMID: 37513726
PMC: 10383313.
DOI: 10.3390/pathogens12070879.
Packard T, Schwarzer R, Herzig E, Rao D, Luo X, Egedal J
mBio. 2022; 13(5):e0189122.
PMID: 36073812
PMC: 9600577.
DOI: 10.1128/mbio.01891-22.
Catchet-MS identifies IKZF1-targeting thalidomide analogues as novel HIV-1 latency reversal agents.
Ne E, Crespo R, Izquierdo-Lara R, Rao S, Kocer S, Gorska A
Nucleic Acids Res. 2022; 50(10):5577-5598.
PMID: 35640596
PMC: 9177988.
DOI: 10.1093/nar/gkac407.
Single-Cell Profiling of Latently SIV-Infected CD4 T Cells Directly to Reveal Host Factors Supporting Reservoir Persistence.
Tokarev A, Machmach K, Creegan M, Kim D, Eller M, Bolton D
Microbiol Spectr. 2022; 10(3):e0060422.
PMID: 35510859
PMC: 9241701.
DOI: 10.1128/spectrum.00604-22.
Heterogeneity of Latency Establishment in the Different Human CD4 T Cell Subsets Stimulated with IL-15.
Butta G, Bozzi G, Gallo G, Copaloni G, Cordiglieri C, Crosti M
J Virol. 2022; 96(10):e0037922.
PMID: 35499323
PMC: 9131862.
DOI: 10.1128/jvi.00379-22.
Human Immunodeficiency Virus-1 Latency Reversal the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation.
Wong L, Li D, Tang Y, Mendez-Lagares G, Thompson 3rd G, Hartigan-OConnor D
Front Microbiol. 2022; 13:836831.
PMID: 35359743
PMC: 8960990.
DOI: 10.3389/fmicb.2022.836831.
A Two-Color Haploid Genetic Screen Identifies Novel Host Factors Involved in HIV-1 Latency.
Roling M, Sisakht M, Ne E, Moulos P, Crespo R, Stoszko M
mBio. 2021; 12(6):e0298021.
PMID: 34872356
PMC: 8649776.
DOI: 10.1128/mBio.02980-21.
Heme Oxygenase-1 Predicts Risk Stratification and Immunotherapy Efficacy in Lower Grade Gliomas.
Ye W, Liu Z, Liu F, Luo C
Front Cell Dev Biol. 2021; 9:760800.
PMID: 34858984
PMC: 8631111.
DOI: 10.3389/fcell.2021.760800.
Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence.
Innis E, Levinger C, Szaniawski M, Williams E, Alcami J, Bosque A
Biochem Pharmacol. 2021; 194:114816.
PMID: 34715067
PMC: 8629953.
DOI: 10.1016/j.bcp.2021.114816.
UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat.
Liang T, Zhang Q, Wu Z, Chen P, Huang Y, Liu S
mBio. 2021; 12(4):e0162521.
PMID: 34465029
PMC: 8406157.
DOI: 10.1128/mBio.01625-21.
Protection of Newborn Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy during Breastfeeding.
Rosenberg Y, Jiang X, Cheever T, Coulter F, Pandey S, Sack M
J Virol. 2021; 95(18):e0026821.
PMID: 34190597
PMC: 8387040.
DOI: 10.1128/JVI.00268-21.
Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques.
Cadena A, Ventura J, Abbink P, Borducchi E, Tuyishime H, Mercado N
Nat Commun. 2021; 12(1):1474.
PMID: 33674572
PMC: 7935896.
DOI: 10.1038/s41467-021-21724-0.
CRISPR based editing of SIV proviral DNA in ART treated non-human primates.
Mancuso P, Chen C, Kaminski R, Gordon J, Liao S, Robinson J
Nat Commun. 2020; 11(1):6065.
PMID: 33247091
PMC: 7695718.
DOI: 10.1038/s41467-020-19821-7.
The HIV-1 latent reservoir is largely sensitive to circulating T cells.
Warren J, Zhou S, Xu Y, Moeser M, MacMillan D, Council O
Elife. 2020; 9.
PMID: 33021198
PMC: 7593086.
DOI: 10.7554/eLife.57246.
Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency.
Stoszko M, Al-Hatmi A, Skriba A, Roling M, Ne E, Crespo R
Sci Adv. 2020; 6(33):eaba6617.
PMID: 32851167
PMC: 7423394.
DOI: 10.1126/sciadv.aba6617.
Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.
Jin H, Li D, Lin M, Li L, Harrich D
Viruses. 2020; 12(4).
PMID: 32276443
PMC: 7232260.
DOI: 10.3390/v12040415.
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity.
Shapiro M, Cheever T, Malherbe D, Pandey S, Reed J, Yang E
Nat Commun. 2020; 11(1):70.
PMID: 31911610
PMC: 6946664.
DOI: 10.1038/s41467-019-13972-y.
